PHAR Earnings Prediction
The chart below shows how PHAR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PHAR sees a +3.87% change in stock price 10 days leading up to the earnings, and a +8.50% change 10 days following the report. On the earnings day itself, the stock moves by -1.94%. This data can give you a slight idea of what to expect for the next quarter's release.
PHAR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
PHAR Earnings Analysis
Pharming Group N.V. ADS, each representing 10 ordinary shares Corporation (PHAR.O) Earnings Conference Call
Positive
Q3 Revenue Increase: Revenue in Q3 increased by 12%.
Product Growth Comparison: RUCONEST grew by 6% and Joenja by 73%.
Gross Profit Increase: Gross profit increased by $9.7 million, aligning with revenue growth.
Operating Profit Increase: Operating profit amounted to $4.1 million compared to $1.9 million last year, indicating strong performance.
Cash Flow Improvement: Cash and cash equivalents increased from $161.8 million to $173.3 million, driven by positive cash flows from operations of $9.7 million.
Negative
Net Loss Decline: The company reported a net loss of $1 million in the quarter compared to a net profit of $3.4 million last year, indicating a significant decline in profitability.
Operating Expenses Concern: Operating expenses increased by 8% from $70.1 million in the second quarter of this year, bringing the year-to-date OpEx to $198.7 million, which raises concerns about cost management.
Revenue Growth Challenges: The total revenues increased by only 12% in Q3, which is lower than expected growth rates, suggesting potential challenges in revenue generation.
Cash Decrease Analysis: The company experienced a decrease in cash and cash equivalents from $215 million at the beginning of the year to $173 million, primarily driven by unfavorable refinancing of convertible bonds earlier this year.
Operating Loss Increase: The operating loss amounted to $15.3 million compared to an operating profit of $6.5 million last year, highlighting a deterioration in operational efficiency.
PHAR FAQs
How does PHAR typically perform around its earnings report dates?
Is Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PHAR Earning Call Sentiment
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PHAR.O
-5.53%Positive
The company shows strong revenue growth, particularly with Joenja, and maintains revenue guidance. However, challenges include increased competition, regulatory hurdles, economic vulnerabilities, and operational expenses. The Q&A reveals management's optimism but also highlights uncertainties in market penetration and patient conversion. No shareholder return plan is announced, and financial health shows a net loss. These mixed factors suggest a neutral stock price movement over the next two weeks.
